Breaking News, Trials & Filings

Trials & Filings in Brief: Sept. 30, 2013

AcelRx, Alnylam, Astellas, Cardiome, DiaMedica, Halozyme, Immunomedics, Lion Biotech, Omeros, Tesaro, USB, Vertex

Phase I
DiaMedica diabetes treatment hits primary endpoints . . . read more

Halozyme gets positive PFS, OS results for PEGPH20 . . . read more

Immunomedics updates ADC results in metastatic colorectal cancer . . . read more

Tesaro begins dose-finding study of rolapitant . . . read more

Phase II
Alnylam completes Phase II enrollment for ATTR . . . read more

Lion’s metastatic melanoma treatment posts positive Phase II results . . . read more

Phase III
Astellas posts positive aspergillosis trial results . . . read more

Filings
AcelRx files NDA for analgesic Zalviso . . . read more

Brinavess approved in South Africa . . . read more

Omeros gets orphan status for PDE10 inhibitor . . . read more

UCB’s Cimzia approved for PsA . . . read more

Vertex files Kalydeco SNDA . . . read more

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters